Mechanism of Action of Ipilimumab
Introduction Ipilimumab is a fully human monoclonal antibody classified under immune checkpoint inhibitors. It plays a pivotal role in cancer immunotherapy by targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a regulatory molecule that downregulates immune responses. By blocking CTLA-4, ipilimumab enhances T-cell activation and proliferation, leading to a more robust antitumor immune response. It has been … Read more